Search for: "Hospira, Inc"
Results 1 - 20
of 287
Sort by Relevance
|
Sort by Date
27 Mar 2024, 4:46 pm
Hospira, Inc., 944 F.3d 1327 (Fed. [read post]
27 Mar 2024, 10:56 am
The 2019 decision Amgen Inc. v. [read post]
5 Mar 2024, 10:23 am
Hospira, Inc., 946 F.3d 1333 (Fed. [read post]
21 Dec 2023, 9:41 am
Hospira, Inc., 946 F.3d 1333, 1340 (Fed. [read post]
31 Jul 2023, 1:51 pm
Hospira, Inc., 946 F.3d 1333, 1338 (Fed. [read post]
31 Jul 2023, 1:47 pm
” Hospira, Inc. v. [read post]
11 Apr 2023, 2:44 pm
” Hospira, Inc. v. [read post]
14 Mar 2023, 4:09 pm
Hospira, Inc., 11 F.4th 1345 (Fed. [read post]
13 Feb 2023, 9:12 pm
By Kevin E. [read post]
22 Sep 2022, 9:43 am
Hospira, Inc., 827 F.3d 1363 (Fed. [read post]
14 Aug 2022, 8:16 pm
Hospira, Inc., 805 F.3d 1112, 1121 (Fed. [read post]
8 Aug 2022, 7:11 am
Hospira, Inc., 11 F.4th 1345 (Fed. [read post]
29 Jul 2022, 12:22 pm
Hospira, Inc., 11 F.4th 1345 (Fed. [read post]
23 Mar 2022, 8:23 am
Hospira, Inc., 52 F. [read post]
5 Mar 2022, 6:35 pm
Hospira, Inc., 946 F.3d 1333, 1337 (Fed. [read post]
7 Feb 2022, 10:32 am
Hospira, Inc., the Eleventh Circuit extended the POM Wonderful rule to Lanham Act claims concerning drug labels. 1 F.4th 1374, 1380–81 (11th Cir. 2021). [read post]
10 Nov 2021, 3:08 am
Hospira, Inc., No. 2020-1799 (Fed. [read post]
10 Nov 2021, 3:08 am
Hospira, Inc., No. 2020-1799 (Fed. [read post]
25 Sep 2021, 9:04 pm
Hospira, Inc., affirming a finding of unenforceability of a patent for inequitable conduct, inferring intent based in part on inconsistent representations that were made by the patentee to the U.S. [read post]
23 Sep 2021, 2:10 am
The US Courts of Appeal of the Federal Circuit (CAFC) found in Belcher Pharmaceuticals v Hospira, Inc that a formulation patent was unenforceable in view of inequitable conduct, in the form of contradictory submissions to the patent office and the regulatory agency (FDA) by the patentee. [read post]
